• HOME
  • TEAM
  • NEWS
  • PORTFOLIO
  • INVESTORS
  • ESG / IMPACT
  • EVENT
  • CONTACT

What are you looking for?

Hadean Ventures
Hadean Ventures
Hadean Ventures
  • HOME
  • TEAM
  • NEWS
  • PORTFOLIO
  • INVESTORS
  • ESG / IMPACT
  • EVENT
  • CONTACT

    @hadeanventures

  • All
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • Current companies
  • Exited companies
  • News
  • Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial

    by @hadeanventures on October 29, 2020

    Safety review of second dose-level cohort allows study to advance to third cohort of colorectal…

    Continue Reading
  • Galecto Announces Pricing of Initial Public Offering

    by @hadeanventures on October 28, 2020

    BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a…

    Continue Reading
  • Neuro Event Labs Receives FDA Breakthrough Device Designation for Nelli®

    by @hadeanventures on October 22, 2020

    SAN ANTONIO (PRWEB) OCTOBER 22, 2020 Neuro Event Labs, Inc., a global diagnostic company, announced that…

    Continue Reading
  • Abliva doses the first patient in its KL1333 Phase Ia/b clinical study

    by @hadeanventures on October 8, 2020

    Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in…

    Continue Reading
  • GALECTO

    by @hadeanventures on September 28, 2020

    Galecto is a Danish drug development company based in Copenhagen...

    Continue Reading
  • Hadean Ventures invest in Galecto`s $64 million round equity financing

    by @hadeanventures on September 25, 2020

    Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple…

    Continue Reading
  • Ingrid Teigland Akay included in Business Insider’s list of 100 People Transforming Business in Europe.

    by @hadeanventures on September 14, 2020

    Ingrid Teigland Akay Managing Partner, Hadean Ventures There’s a growing desire among investors not only…

    Continue Reading
  • Abliva intends to start a pivotal KL1333 study second half 2021

    by @hadeanventures on September 9, 2020

    Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided…

    Continue Reading
  • Oncoinvent Advances Radspherin[®] to Second Dose Level in Ongoing Phase 1 Clinical Trial

    by @hadeanventures on September 4, 2020

    FRI, SEP 04, 2020 09:19 CET Safety review of first dose-level cohort allows progression to…

    Continue Reading
  • Pewin Member Highlight 2020: Ingrid Teigland Akay

    by @hadeanventures on August 14, 2020

    Continue Reading
  • ←
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • →

Member of

Designed and developed by PageLook.no
Privacy Policy